StockData

TuHURA Biosciences vs NextCure

HURA and NXTC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How HURA and NXTC compare

TuHURA Biosciences is the larger company, worth 2.9 times as much as NextCure ($89.2M against $30.7M).

NextCure scores higher on the StockData Score (5 against 0 for TuHURA Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricHURANXTC
Size and price
Market cap$89.2M$30.7M
Share price$1.40$6.70
Change, 1 year−31.7%−32.2%
Change, 5 years−99.9%−90.7%
Beta (5Y)1.982.04
Employees2240
StockData Score
Total score05 (better)
Valuation score00
Growth score00
Performance score00
Health score05 (better)
Dividend score00
Valuation
P/B4.8×2.5× (better)
FCF yield−33.5%–
Profitability
Return on equity−161% (better)−205%
Return on invested capital–−320%
Financial health
Debt / equity–0.00
Current ratio0.183.47 (better)
Altman Z-score−3.21 (better)−32.32
Piotroski F-score2 (better)1
Dividends and buybacks
Dividend yield–0.00%
Years of dividend growth–0
Buyback yield−22.6%–
Shareholder yield−22.6%0.00% (better)
Ownership
Held by institutions14.1%37.9%
Held by insiders4.9%22.9%
Insider net buying, 12 months–$1.7M
Short interest, % of float10.2%5.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.